

Mangalam Drugs and Organics Ltd.



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
☎ 91-22-22616200 / 6300 / 8787 ☎ 91-22-22619090 • CIN : L24230MH1972PLC116413

REF: MDOL/CS-SE/2022-23/034

November 17, 2022

To,
Listing Department
BSE Ltd
1st Floor, New Trade Wing,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001.

Listing Department
National Stock Exchange of India
Limited
“Exchange Plaza”, 5th Floor,
Plot No. C-1, Block G,
Bandra - Kurla Complex,
Bandra(E), Mumbai – 400 051

Scrip Code: 532637

Symbol: MANGALAM

Subject: Newspaper Advertisement regarding publication of Un-Audited Financial Results for the period ended September 30, 2022

Dear Sir / Madam,

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed herewith copies of newspaper advertisement for Un-Audited Financial Results of the Company for the period ended September 30, 2022 published in Financial Express (English daily) and Loksatta (Marathi daily).

Kindly take the above information on your records.

Thanking You,

Yours Faithfully,
For Mangalam Drugs & Organics Limited

GOVARDHAN
N
MURLIDHAR
DHOOT

Digitally signed by:
GOVARDHAN
MURLIDHAR DHOOT
DN: CN = GOVARDHAN
MURLIDHAR DHOOT C =
IN O = Personal
Date: 2022.11.17 11:06:01
+05'30'

Govardhan M. Dhoot
Chairman & Managing Director
DIN: 01240086

DELTA INDUSTRIAL RESOURCES LIMITED

CIN: L52110DL1984PLC019625

Regd. Off: 325, 3rd Floor, Aggarwal Plaza, Sector-14, Rohini, New Delhi-110 085
Ph: 9810260127 | Email Id: deltaindlt@gmail.com | Website: www.dirl.in**Extracts of the Standalone Financial Results
For the Quarter and Half Year Ended September 30, 2022**

Sl. No.	Particulars	Quarter Ended		
		30/09/2022		30/09/2022
		(Un-Audited)	(Un-Audited)	(Un-Audited)
1.	Total income from operations	9.63	27.17	21.60
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	5.80	(4.81)	13.31
3.	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	5.80	(4.81)	13.31
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	7.68	(3.59)	13.30
5.	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) & other Comprehensive Income (after tax))	8.09	(3.71)	13.84
6.	Equity Share Capital	539.30	539.30	539.30
7.	Reserves (excluding Revaluation Reserve as shown in the Audited Balance Sheet of previous year)	(57.98)	(49.27)	(57.98)
8.	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations) -			
	1. Basic :	0.25	(0.07)	0.25
	2. Diluted :	0.25	(0.07)	0.25

NOTE:
1. The above is an extract of the detailed format of Un-audited Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Un-Audited Quarterly Financial Results are available on the Website of the Company i.e (www.dirl.in) and website of the stock exchange(s) (www.bse-india.com) and (www.nseindia.com).
2. The above result have been reviewed by the audit committee and approved by the Board at their meeting held on 10th November, 2022.
3. The Financial results have been prepared in accordance with the Indian Accounting Standards (IND-AS) as prescribed under section 133 of the Companies Act, 2013 read with IND-AS rules (As amended).

For and on behalf of the Board of Directors of
Delta Industrial Resources LimitedSd/-
Pawan Kumar Mittal (Director)
DIN: 00749265Date: 10.11.2022
Place: New Delhi**MASK INVESTMENTS LIMITED**

CIN : L65993GJ1992PLC036653

REGD. OFFICE : 6th FLOOR, A/601-B, INTERNATIONAL TRADE CENTRE, MAJURA GATE, RING ROAD, SURAT - 395 002 (GUJARAT) INDIA. Ph: +91-261-2463261 / 62 / 63. Fax: +91-261-2463264.
Email : contact@maskinvestments.com, website : www.maskinvestments.com**EXTRACT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2022**

PARTICULARS	(Rs. in Thousands)		
	STANDALONE		Quarter Ended
	Quarter Ended	Six Months Ended	Quarter Ended
	30/09/2022	30/09/2022	30/09/2022
	(Unaudited)	(Unaudited)	(Unaudited)
Total income from Operations	560.11	819.20	574.42
Net Profit for the period (before Tax, Exceptional and / or Extraordinary Items)	355.78	100.24	194.33
Net Profit for the period before tax (after Exceptional and / or Extraordinary Items)	355.78	100.24	194.33
Net profit for the period after tax (after Exceptional and / or Extraordinary Items)	266.23	75.01	145.41
Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	1,29,424.77	2,61,013.60	11,168.99
Paid up Equity Share Capital	30,515.00		
Reserves (excluding Revaluation Reserve) as shown in Balance sheet of previous year (as on 31/03/2022)	6,90,902.01		
Earning Per Share (Face Value of Rs.10/- each) (for continuing and discontinued operations)			
(a) Basic (In Rs.) :	0.09	0.02	0.05
(b) Diluted (In Rs.) :	0.09	0.02	0.05

NOTE:
1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on 11th November, 2022.
2. The above is an extract of the detailed format of Unaudited Standalone Financial Results for the Quarter ended 30th September, 2022 filed with stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly financial results is available on the Stock Exchange website i.e www.nseindia.com and on the Company's website i.e www.maskinvestments.com.

For MASK INVESTMENTS LIMITED

Sd/-
NARAYAN SABOO
DIRECTORPlace: SURAT
Date: 11/11/2022**MANGALAM DRUGS & ORGANICS LIMITED.**

Regd Off: Rupam Building, 3rd Floor, 239 PD/Mello Road, Near GPO, Mumbai - 400 001

Tel. No. 91-22-22616200 / 6300/8787 Fax No. 91-22-2619090
CIN - L24230MH1972PLC116413

Email : contactus@mangalamdrugs.com Website : http://www.mangalamdrugs.com

Unaudited Financial Results for the Quarter and Half year Ended 30th September 2022

Particulars	(Rs. in Lakhs)					
	QUARTER ENDED		HALF YEAR ENDED		YEAR ENDED	
	30/09/2022	30/06/2022	30/09/2021	30/09/2022	30/09/2021	31/03/2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Total Income from Operations (net)	10,832.57	10,949.49	12,302.33	21,782.06	22,832.40	45,106.84
2 Profit / (Loss) before finance cost and exceptional and extraordinary items and tax	567.67	778.27	1,126.09	1,345.94	1,974.20	3,899.48
3 Profit/(Loss) before tax and after exceptional & extraordinary items	312.17	423.79	828.30	735.96	1,380.15	2,773.30
4 Net Profit/(Loss) after Tax	222.62	300.38	452.81	523.00	894.39	1,965.75
5 Total Comprehensive Income	225.57	303.33	454.86	528.90	898.50	1,977.54
6 Paid-up Equity Share Capital (Face value of Rs 10/- per share)	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82	1,582.82
7 Other Equity	-	-	-	-	-	13,473.32
8 Earnings Per Share (EPS) (of Rs 10/- each not annualised):						
(a) Basic	1.41	1.92	2.86	3.30	5.65	12.42
(b) Diluted	1.41	1.92	2.86	3.30	5.65	12.42

NOTES:
The above is an extract of the detailed format of Unaudited Standalone Financial Results for the Quarter and half year ended 30th September, 2022 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing obligation and Disclosure Requirements) Regulations 2015. The full format of the Standalone Financial Results for the period ended 30th September, 2022 is available on the Stock Exchange website & the Company's website. (www.bseindia.com and www.nseindia.com and www.mangalamdrugs.com)

For & on Behalf of the Board
For Mangalam Drugs & Organics LimitedSd/-
SHREE GOVARDHAN M.DHOOT
CHAIRMAN & MANAGING DIRECTOR

DIN: 01240086

Place: Mumbai
Date: 11th November, 2022**Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]**

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),

Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481

Tel. No.: (+91-79) 4804 0100 Website: www.zyduslife.com

CIN : L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter and Half Year Ended 30/09/2022

Sr. No.	Particulars	in Million					
		3 Months ended		Preceding 3 Months ended		Year to date figures for the current period	
		30/09/2022	30/06/2022	30/09/2021	30/09/2021	30/09/2022	30/09/2021
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
1	Total income from operations	41,347	40,727	37,598	82,074	77,616	1,52,652
2	Net Profit for the period before exceptional items and tax	6,428	6,839	7,454	13,267	15,483	27,254
3	Net Profit for the period after exceptional items but before tax	6,428	6,810	8,581	13,238	16,610	28,381
4	Net Profit for the period from continuing operations	5,170	5,266	7,251	10,436	13,223	22,416
5	Profit/ (Loss) after tax from discontinued operations	55	(83)	22,772	(28)	22,672	22,457
6	Net Profit for the period after tax and Non-Controlling Interest	5,225	5,183	30,023	10,408	35,895	44,873
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	4,357	3,608	30,139	7,965	35,607	43,832
8	Paid-up equity share capital (Face value ₹ 1/-)	1,012	1,024	1,024	1,012	1,024	1,024
9	Reserves excluding Revaluation Reserve (i.e. Other Equity)						1,68,972
10	Earnings per share for continuing operations (not annualised for the quarter and half year)						
	a Basic (₹)	5.10	5.14	7.08	10.24	12.92	21.90
	b Diluted (₹)	5.10	5.14	7.08	10.24	12.92	21.90
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter and half year)						
	a Basic (₹)	5.15	5.06	29.33	10.21	35.06	43.83
	b Diluted (₹)	5.15	5.06	29.33	10.21	35.06	43.83

NOTE:
[1] The above is an extract of the detailed format of Quarterly/Half yearly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly/Half yearly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE (www.bseindia.com) and on the website of NSE (www.nseindia.com).

By Order of the Board,
For Zydus Lifesciences Limited,Dr. Sharvil P. Patel
Managing Director
DIN: 00131995

Ahmedabad, November 11, 2022

JITF INFRALOGISTICS LIMITED

CIN - L60231UP2008PLC069245

Regd. Office: A-1, UPSIDC Indl. Area, Nandgaon Road, Kosi Kalan, Distt. Mathura (U.P.)-281403

EXTRACT OF FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2022

Sl. No.	Particulars	Standalone					Consolidated						
		Quarter Ended		Half Year Ended		Year Ended	Quarter Ended		Half Year Ended		Year Ended		
		30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	30.09.2022	30.06.2022	30.09.2021	30.09.2022	30.09.2021	31.03.2022	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
1	Total Income from operations	66.51	70.24	62.87	136.75	135.43	276.71	27,045.29	25,008.43	22,867.27	52,053.72	43,450.71	123,478.91
2	Net Profit / (Loss) for the period/year (before Tax and Exceptional items)	3.16	11.09	5.57	14.25	10.97	25.59	(3,107.36)	(3,745.20)	(4,540.74)	(6,852.56)	(8,022.79)	(12,717.76)
3	Net Profit / (Loss) for the period/ year before Tax (after Exceptional items)	3.16	11.09	5.57	14.25	10.97	25.59	(3,103.31)	(3,743.25)	(4,542.45)	(6,846.56)	(8,024.81)	(12,703.51)
4	Net Profit / (Loss) for the period/year after Tax (after Exceptional items)	2.35	8.29	3.98	10.64	7.96	19.14	(3,311.85)	(3,599.71)	(4,246.01)	(6,911.56)	(7,809.64)	(12,876.09)
5	Total Comprehensive Income for the period/year (Comprising Profit/(Loss) for the period/year (after tax) and Other Comprehensive income (after tax))	2.84	8.78	4.16	11.62	8.31	21.09	(3,064.54)	(3,594.22)	(4,228.95)	(6,658.76)	(7,726.12)	(12,711.54)
6	Equity Share Capital	514.07	514.07	514.07	514.07	514.07	514.07	514.07	514.07	514.07	514.07	514.07	514.07
7	Reserves (excluding Revaluation Reserve) as at Balance Sheet date						31,508.04						(77,136.22)
8	Earnings Per Share (of ₹ 2/- each)												
	(1) Basic (₹)	0.01	0.03	0.02	0.04	0.03	0.07	(13.50)	(15.16)	(17.67)	(28.66)	(33.47)	(55.97)
	(2) Diluted (₹)	0.01	0.03	0.02	0.04	0.03	0.07	(13.50)	(15.16)	(17.67)	(28.66)	(33.47)	(55.97)

NOTE:
1) The above is an extract of the detailed format of quarterly/half yearly/ annual financial results filed with the stock exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the quarterly/half yearly/ annual financial results are available on the stock exchanges websites, www.nseindia.com, www.bseindia.com and on the Company's website, www.jindalinfra.logistics.com.

On behalf of Board of Directors of JITF InfraLogistics Limited

Amarendra Kumar Sinha
Whole Time Director

DIN : 08190565

Place : New Delhi
Date : 11th November, 2022**RAVINDER HEIGHTS LIMITED**

CIN: L70109PB2019PLC049331

Regd. Off.: SCO No. 71, First Floor, Royal Estate Complex, Zirakpur, Punjab-140603

Website: www.ravinderheights.com • Email: info@ravinderheights.com

Telephone: +91-11-43639000; • Fax: +91-11-43639015



RAVINDER HEIGHTS

Sr. No.	Particulars	(Rs. In Lakh except earnings per share)											
		STANDALONE					CONSOLIDATED						
		Quarter ended		Half year ended		Financial Year Ended	Quarter Ended		Half Year Ended		Financial Year Ended		
		September 30, 2022	June 30, 2022	September 30, 2021	September 30, 2022	September 30, 2021	March 31, 2022	September 30, 2022	June 30, 2022	September 30, 2021	September 30, 2022	September 30, 2021	March 31, 2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1	Total Income from Operations	35.28	35.28	35.28	70.56	70.60	141.16	9.93	2.77	0.78	12.70	1.60	3.36
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(25.36)	(15.81)	0.40	(41.18)	(4.16)	(28.43)	(107.89)	(104.44)	17.31	(212.35)	27.09	(56.52)
3	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	(25.36)	(15.81)	0.40	(41.18)	(4.16)	(28.43)	(107.89)	(104.44)	17.31	(212.35)	27.09	(56.52)
4	Net Profit / (Loss) for the period after tax of continuing operations (after Exceptional and/or Extraordinary items)	(23.20)	(10.32)	7.72	(33.52)	(1.27)	(16.39)	(87.42)	(79.78)	0.30	(167.22)	(17.96)	(42.52)
5	Net Profit / (Loss) for the period after tax of discontinued operations (after Exceptional and/or Extraordinary items)	-	-	-	-	-	-	6.59	5.29	228.42	11.87	230.47	40.34
6	Total Comprehensive Income for the period (Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax))	(23.20)	(10.32)	7.72	(33.52)	(1.27)	(16.39)	(80.84)	(74.49)	228.72	(155.35)	212.51	(2.17)
7	Equity Share Capital	612.51	612.51	612.51	612.51	612.51	612.51	612.51	612.51	612.51	612.51	612.51	612.51
8	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	-	-	-	-	-	-	-	-
9	Earnings Per Share (of Re 1/- each) (for continuing and discontinued operations) -												
	1. Basic & Diluted for Continuing Operations	(0.04)	(0.02)	0.01	(0.05)	0.00	(0.03)	(0.13)	(0.12)	0.37	(0.25)	0.35	0.00
	2. Basic & Diluted for Discontinued Operations	-	-	-	-	-	-	0.01	0.0				